Last year, the Argentinean government nationalized 51% of YPF (YPF) from Madrid based Repsol (REPYY), which still holds a 12.4% stake in Argentina's biggest oil and gas company. When the nationalization happened, Argentina's government argued that the Spanish group had not been investing enough in the country. Hence, the lack of investments had left Argentina without its very much appreciated external surplus in oil and gas. Even when its true that YPF's Capex investments were kept at a minimum level from 2003 to 2011, its also true that low Capex was a direct result of Argentina's (very) poor and unsustainable energy policies.
After the nationalization happened, no compensation had been awarded to Repsol until now. As a result, the Spanish oil company had started international legal actions against Argentina. Miguel Galuccio, YPF's new CEO - who is the best CEO the company has had since Jose Estenssoro died in 1995 - has been also pushing president Cristina Kirchner to arrange a final settlement with Repsol. He had been looking for partners to invest along YPF in the Vaca Muerta formation, one of the world's most promising shale oil and gas reserves, since he accepted the Chairmanship in 2012. Finding partners without a settlement with Repsol was not easy. Only Chevron (CVX) had agreed to make a $1.2 billion investment before the settlement with Repsol arrived. Argentina needs many more billions in order to develop its huge shale reserves. Now, the country and YPF's CEO might get all the investments Vaca Muerta needs.
Hot Cheapest Companies To Buy For 2015: CBIZ Inc (CBZ)
CBIZ, Inc. (CBIZ) provides professional business services, products and solutions. These services are provided to businesses of various sizes, as well as individuals, governmental entities and not-for-profit enterprises throughout the United States and parts of Canada. CBIZ delivers its services through four practice groups: Financial Services, Employee Services, and National Practices. Its Financial Services group includes accounting, tax, financial advisory, valuation, litigation support, internal audit, family office services, fraud detection and real estate advisory. Its Employee Services group provides group health, property and casualty, retirement planning, payroll services, life insurance, human capital management, compensation consulting, recruiting and actuarial services. MMP group includes coding and billing, accounts receivable management and full practice management services. National Practices group includes managed networking and hardware services, health care consulting, and mergers and acquisitions. Effective July 1, 2012, the Company acquired the assets of Stoltz and Company, LTD., L.L.P. In October 2012, it acquired the assets of ProMedical, Inc. On December 31, 2012, the Company acquired the non-attest assets of PHBV Partners, L.L.P. Effective May 1, 2013, it announced that it has acquired Associated Insurance Agents. In September 2013, CBIZ, Inc completed the sale of its Medical Management Professionals (MMP) business to Zotec Partners, LLC.
On January 1, 2011, CBIZ sold its individual wealth management business. Effective November 1, 2011, the Company acquired the defined benefit actuarial consulting practice of PSA Insurance and Financial Services of Hunt Valley, Maryland. During the year ended December 31, 2011, CBIZ acquired four businesses: Thompson Dunavant PLC, Gresham Smith LLC, Multiple Benefit Services, Inc. and Atlantic MDR, LLC (d/b/a Advantage Benefit Planning). On January 1, 2012, the Company acquired Meridian Insurance Group, LLC.
Financial! Services
The Financial Services practice is divided into a Financial Services division, representing the United States, and a National Services division consisting of those units that provide their services nationwide. CBIZ and its subsidiaries maintain joint-referral relationships and administrative service agreements (ASAs) with independent licensed Certified Public Accounting (CPA) firms under which audit and attest services may be provided to CBIZ�� clients by such CPA firms. Under these ASAs, CBIZ provides a range of services to the CPA firms, including (but not limited to) administrative functions, such as office management, bookkeeping, and accounting, preparing marketing and promotion materials, providing office space, computer equipment, and systems support, and leasing administrative and professional staff. As of December 31, 2011, CBIZ maintained ASAs with four CPA firms.
Employee Services
The business units that comprise CBIZ�� Employee Services group are organized between Retail and National Services. The Retail offices provide services within their geographic area. The National group includes a number of specialty operations that provide services on a national scale. CBIZ�� Employee Services group maintains relationships with different insurance carriers. Some of these carriers have compensation arrangements.
National Practices
The National Practices group offers technology, health care consulting, and merger and acquisition services. The units within the National Practices group each have a Business Unit President.
Advisors' Opinion:- [By Seth Jayson]
CBIZ (NYSE: CBZ ) reported earnings on July 29. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), CBIZ whiffed on revenues and missed estimates on earnings per share.
Top 10 Promising Stocks To Own For 2014: Akorn Inc.(AKRX)
Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. It offers products in various specialty areas, including ophthalmology, antidotes, anti-infectives, pain management, anesthesia, and vaccines. The company?s Ophthalmic segment markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes, and others primarily for use in the office setting. This segment also offers therapeutic products, such as antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers, chain drug stores, and other national account customers; and non-pharmaceutical products, which include various artificial tear solutions, preservative-free lubricating ointments, and eyelid cleansers. In addit ion, the Ophthalmic segment provides a line of over-the-counter dry eye and other eye health products principally under the TheraTears brand name through a chain drug stores and big box retailers, as well as directly to optometrists, ophthalmologists, and other eye care practitioners and clinics. The company?s Hospital Drugs and Injectables segment provides a line of niche hospital drug and injectable pharmaceutical products comprising antidotes, anti-infectives, controlled substances for pain management and anesthesia, and other pharmaceutical products to hospitals through the wholesale distribution channel. Its Contract Services segment manufactures ophthalmic and injectable pharmaceutical products for third party pharmaceutical customers based on their specifications. The company serves physicians, optometrists, hospitals, wholesalers, group purchasing organizations, pharmacy chains, and other pharmaceutical companies. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of Akorn (NASDAQ: AKRX) were down 9.41 percent to $23.39 after the company reported Q4 results and issued a weak FY14 guidance. - [By Sean Williams]
What: Shares of Akorn (NASDAQ: AKRX ) �-- a hybrid generic and branded drug developer -- shed as much as 15% of their value after the company reported disappointing first-quarter results.
- [By Ben Levisohn]
Still, some stocks are bucking the trend. Goodyear Tire & Rubber (GT) has gained 1.4% to $18.90, the largest gainer in the S&P 500, after reaching a deal with a union. The real winners: Hi-Tech Pharmacal (HITK) has gained 22.3% to $43.05 after agreeing to be purchased by Akorn (AKRX), which has jumped 9.6% to $18.02.
Top 10 Promising Stocks To Own For 2014: A. Schulman Inc.(SHLM)
A. Schulman, Inc. supplies plastic compounds and resins for packaging, consumer products, industrial, and automotive applications. The company offers additive compounds, custom color concentrates for film and molding, carbon black color concentrates, white color concentrates, additive compounds for polyester resins and special pearl effects, antistatic concentrates, and masterbatch for the production of synthetic paper. Its products also include engineered plastics, such as thermoplastic elastomers and vulcanizates, filled and unfilled nylon and PBT compounds, nylon/ABS alloys, formulated ionomer compounds, thermoplastic ionomer resins, flame-retardant thermoplastic compounds and concentrates, polypropylene, polyethylene, EVA compounds, thermoplastic olefins, flexible thermoplastic PVC compounds, high-quality PVC compounds, PVC-based thermoplastic elastomers, and low-gloss PVC thermoplastic elastomers for industrial packaging, appliances, electrical connectors, power tools , recreational items, and lawn and garden equipments. In addition, the company provides custom color and specialty compound powders, rotational molding process compounds, cross-linkable resin used in rotational molding, high heat-distortion temperature materials, and thermoplastic powders, as well as provides jet milling services used for products requiring very fine particle size, such as additives for printing ink, adhesives, waxes, and cosmetics; and cryogenic milling services for heat sensitive materials. Further, it buys, repackages, and re-sells polymers for various processing types comprising injection molding, blow molding, thermoforming, and extrusion, as well as provides tolling services. The company operates in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. A. Schulman, Inc. was founded in 1928 and is headquartered in Akron, Ohio.
Advisors' Opinion:- [By Eddie Staley]
Basic materials sector was the top gainer in Wednesday’s trading. Top gainers in the sector included A. Schulman (NASDAQ: SHLM), up 4.63 percent, and Cliffs Natural Resources (NYSE: CLF), up 4.87 percent.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on A. Schulman (Nasdaq: SHLM ) , whose recent revenue and earnings are plotted below. - [By Maria Armental var popups = dojo.query(".socialByline .popC"); popups.forEach]
A. Schulman Inc.(SHLM) agreed to buy a majority of Ferro Corp.'s(FOE) specialty plastics business for $91 million in cash, an effort to expand its geographic footprint.
- [By Ben Levisohn]
A. Shulman (SHLM) has gained 6.4% to $38.65 after the plastic maker beat earnings forecasts and lifted its full-year guidance.
Gilead Sciences (GILD) has dropped 1% to $71.48 on reports that Express Scripts (ESRX) wants the biotech giant to lower the price of its hepatitis C drug, Sovaldi. Express Scripts has gained 0.6% to $73.16.
Top 10 Promising Stocks To Own For 2014: Cigna Corp (CI)
Cigna Corporation (Cigna), incorporated on November 3, 1981, is a holding company. Cigna is a global health service company, with insurance subsidiaries that are providers of medical, dental, disability, life and accident insurance and related products and services. In the United States, these products and services are offered through employers and other groups, and in selected international markets, Cigna offers supplemental health, life and accident insurance products and international health care coverage and services to businesses, governmental and non-governmental organizations and individuals. The Company also has certain run-off operations, including a Run-off Reinsurance segment. Cigna�� revenues are derived from premiums, fees, mail order pharmacy, other revenues and investment income. Cigna operates in five segments: Health Care, Disability and Life, International, Run-off Reinsurance, and Other Operations, including Corporate-owned Life Insurance. On January 31, 2012, Cigna acquired HealthSpring, Inc. On November 30, 2011, the Company acquired FirstAssist Group Holdings Limited. In August 2012, the Company acquired Great American Supplemental Benefits from American Financial Group, Inc. In January 2013, the Company acquired select Arcadian and Humana Medicare Advantage plans in Arkansas, Oklahoma and Texas. In September 2013, Cigna Corporation completed its acquisition of Alegis Care, a portfolio company of Triton Pacific Capital Partners. Effective September 3, 2013, Cigna Corp acquired Home Physicians Management LLC.
Health Care
Cigna�� Health Care segment (Cigna HealthCare) offers insured and self-insured medical, dental, behavioral health, vision, and prescription drug benefit plans, health advocacy programs and other products and services that may be integrated to provide health care benefit programs. Cigna HealthCare companies offer these products and services in all 50 states, the District of Columbia and the United States Virgin Islands. Cigna offers a ! range of products and services to employers and other groups that sponsor group health plans. With the exception of Health Maintenance Organization (HMO), Medicare, Voluntary and stop loss products, each of Cigna HealthCare�� products is offered with alternative funding options. Cigna may sell multiple products under the same funding arrangement to the same employer. Approximately 85% of the Company�� medical customers are enrolled in self-insured plans, with the remainder split between guaranteed cost and experience-rated insured plans. Approximately 90% of its medical customers are enrolled in self-insured and experience-rated plans. Cigna also offers guaranteed cost medical and dental insurance to individuals. Cigna HealthCare offers a product line of indemnity managed care benefit plans on an insured (guaranteed cost or experience-rated) or self-insured basis. The Network, Network Open Access, and Open Access Plus In-Network products cover only those services provided by Cigna HealthCare participating health care professionals (in-network) and emergency services provided by non-participating health care professionals (out-of-network). The Network point of service (POS), Network POS Open Access and Open Access Plus plans (OAP) cover health care services provided by participating, and non-participating health care professionals.
Cigna HealthCare offers a Preferred Provider Plans (PPO) product line that features a national network. Like Network and Open Access Plus Plans, the PPO product line is offered on an insured (guaranteed cost or experience-rated) or self-insured basis. Cigna HealthCare offers the Cigna Choice Fund suite of products, including Health Reimbursement Accounts (HRA), Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). Cigna HealthCare offers stop loss insurance coverage for self-insured plans. This stop loss coverage reimburses the plan for claims in excess of a predetermined amount, either for individuals (specific) or the entire group (aggregate), ! or both. ! Cigna HealthCare provides Taft-Hartley trusts and other entities access to its national provider network and provides claim re-pricing and other services. Cigna HealthCare�� voluntary medical products are offered to employers with 51 or more eligible employees. As a result of the acquisition of HealthSpring, Cigna operates Medicare Advantage coordinated care plans in 11 states and the District of Columbia. Under the Medicare program, Medicare-eligible beneficiaries may receive health care benefits, including prescription drugs, through a managed care health plan, such as the Company�� coordinated care plans, and The Centers for Medicare and Medicaid Services reimburse the Company pursuant to a risk adjustment payment methodology.
Cigna�� Medicare Part D prescription drug program, Cigna Medicare Rx, provides a number of plan options, as well as service and information support to Medicare and Medicaid eligible customers. Cigna Medicare Rx is available in all 50 states and the District of Columbia. Cigna HealthCare offers medical management, disease management, and other health advocacy services to employers and other plan sponsors. These services are offered to customers covered under Cigna HealthCare administered plans, as well as individuals covered under plans insured and/or administered by competing insurers/third-party administrators. Cigna�� onsite services include more than 75 health centers and the annual administration of more than 400,000 biometric screenings, as well as approximately 2,200 wellness seminars each year. As a result of the acquisition of HealthSpring, Cigna operates three LivingWell Health Centers, where Medicare customers can receive care from physicians, nurse practitioners, nurses, pharmacists, and nurses educators. Cigna arranges for behavioral health care services for customers through its network of participating behavioral health care professionals. Cigna offers behavioral health care case management services, employee assistance programs (EAP), and wor! k/life pr! ograms to employers, Government entities and other groups sponsoring health benefit plans. As of December 31, 2011, Cigna�� behavioral national network had approximately 108,000 access points to psychiatrists, psychologists and clinical social workers and approximately 9,000 facilities and clinics.
Cigna Pharmacy Management offers prescription drug plans to its insured and self-funded customers both in conjunction with its medical products and on a stand-alone basis. With a network of over 62,000 contracted pharmacies, Cigna Pharmacy Management is a pharmacy benefits manager (PBM) offering clinical integration programs, specialty pharmacy solutions and home delivery of prescription medicines. Cigna�� specialty pharmacy outcome management program, TheraCare, manages specialty conditions. TheraCare is coordinated with other Cigna health advocacy programs and all data is captured for analysis and reporting. Cigna Dental Health offers a variety of dental care products, including dental health maintenance organization plans (Dental HMO), dental preferred provider organization (DPPO) plans, dental exclusive provider organization plans, traditional dental indemnity plans and a dental discount program. As of December 31, 2011, Cigna Dental Health customers totaled approximately 10.9 million. Managed dental care products are offered in 38 states for Dental HMO and 43 states and the District of Columbia for Dental PPO through a network of independent health care professionals that have contracted with Cigna Dental Health to provide dental services. Cigna Dental Health customers access care from the dental PPO network in the United States and one of the dental HMO networks in the United States, with approximately 235,500 DPPO-contracted access points (approximately 92,000 health care professionals) and approximately 58,000 dental HMO-contracted access points (approximately 16,500 health care professionals).
Disability and Life
Cigna�� Disability and Life segment (Cign! a Disabil! ity and Life) provides insurance products and their related services, such as group long-term and short-term disability insurance, group life insurance and accident and specialty insurance. These products and services are provided by subsidiaries of Cigna Corporation. Cigna Disability and Life markets products in all 50 states, the District of Columbia, Puerto Rico, the United States Virgin Islands and Canada. Cigna Disability and Life also provides assistance to employees in returning to work and assistance to their employers in managing the cost of employee disability. Cigna Disability and Life offers personal accident insurance coverage, which consists primarily of accidental death and dismemberment and travel accident insurance to employers. Group accident insurance may be employer-paid or employee-paid. Cigna Disability and Life also offers specialty insurance services that consist primarily of disability and life, accident, and hospital indemnity products to professional or trade associations and financial institutions.
International
CIGNA�� International segment (CIGNA International) offers supplemental health, life and accident insurance products, as well as international health care products and services. These products and services are provided by subsidiaries of Cigna Corporation, including foreign operating entities. Cigna International provides employers, affinity groups and individuals with local and global health care and related financial protection programs. Supplemental health products provide a specified payment for a range of health risks and include personal accident, accidental death, critical illness, hospitalization, travel, dental, cancer and other dread disease coverages. Term life, as well as variable universal life insurance and other savings products are also included in the product portfolio. Cigna International�� supplemental health, life and accident insurance products are offered in South Korea, Taiwan, Indonesia, Hong Kong, the European Un! ion, Chin! a, New Zealand, Thailand and Turkey. In China, Cigna International owns a 50% interest in a joint venture through, which its products and services are offered. Cigna International�� health care businesses primarily consist of products and services to meet the needs of local and multinational companies and organizations and their local and globally mobile employees and dependents. These products and services include insurance and administrative services for medical, dental, vision, life, accidental death and dismemberment, and disability risks. In addition, Cigna International�� health care businesses include products and services, which are primarily provided through group benefits programs to employees of businesses and other organizations in the United Kingdom and Spain. These products and services include medical indemnity insurance coverage, with some offerings having managed care or administrative service aspects.
Run-off Reinsurance
Cigna�� reinsurance segment reinsured guaranteed minimum death benefits (GMDB) (also known as variable annuity death benefits (VADBe)), under certain variable annuities issued by other insurance companies. These variable annuities are investments in mutual funds combined with a death benefit. The Company purchased retrocessional protection that covers approximately 5% of the assumed risks. The Company also maintains a dynamic hedge program. Cigna also reinsured guaranteed minimum income benefits (GMIB) under certain variable annuities issued by other insurance companies. These variable annuities are investments in mutual funds combined with minimum income and death benefits. These products under Cigna�� Run-off Reinsurance segment were sold principally in North America and Europe through a sales force and through intermediaries.
Other Operations
The principal products of the Corporate-owned Life Insurance (COLI) business are permanent insurance contracts sold to corporations to provide coverage on the lives ! of certai! n employees for the purpose of funding employer-paid future benefit obligations. The principal services provided by the COLI business are issuance and administration of the insurance policies. COLI policies provide a death benefit for which Cigna collects fees to cover mortality risk. COLI policies also allow policy owners to borrow against a portion of their cash surrender value.
Advisors' Opinion:- [By Michael A. Robinson]
So, it's a pretty safe bet that if a health insurer like Cigna Corp. (NYSE: CI) or Blue Cross Blue Shield messed up this badly, heads would roll.
For Sebelius and even for Obama himself, the problem actually runs much deeper than it appears.
Top 10 Promising Stocks To Own For 2014: FCCC Inc (FCIC)
FCCC, Inc. (FCCC), incorporated on March 21, 1960, is focused on merger, acquisition, reverse merger or a business transaction opportunity with an operating business or other financial transaction. The Company has not restricted its search to any particular business, industry or geographical location.
As of March 31, 2013, the Company had no arrangements or understandings with respect to any merger, acquisition, reverse merger or business combination candidate. The Company has limited operations and is actively seeking merger, reverse merger, acquisition or business combination opportunities with an operating business or other financial transaction opportunities.
Advisors' Opinion:- [By The Science of Hitting]
After the financial crisis, the Financial Crisis Inquiry Commission (FCIC) was created to determine the root cause of the crisis; as part of that effort, the commission was required to make the ensuing interviews of hedge fund managers, bankers, and economists available to the public. One of the people interviewed was Warren Buffett, and as expected, he didn�� disappoint. During the interview, he was asked to discuss the difference between investment and speculation; here was his response (bold added for emphasis):
Top 10 Promising Stocks To Own For 2014: Amgen Inc.(AMGN)
Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Advisors' Opinion:- [By Maxx Chatsko]
In the following video, Fool contributor Maxx Chatsko explains whether he thinks Gilead Sciences (NASDAQ: GILD ) or Amgen (NASDAQ: AMGN ) is the better buy. Both companies are trading at nearly identical market caps and have risen dramatically since the beginning of 2012 in anticipation of new blockbuster products. Both have robust pipelines stuffed full of potential at all levels of development. This is going to be a tough decision. If these companies are on your watchlist or if you're simply looking to add to a position, then you may want to use the current market volatility to your advantage.
- [By Garrett Cook]
BIND Therapeutics (NASDAQ: BIND) was down, falling 10.56 percent to $11.52 after the company reported the closing of collaboration deal with Amgen (NASDAQ: AMGN).
- [By Ben Levisohn]
Lower cholesterol means a higher price for Amgen’s (AMGN) stock–but could be bad news for Regeneron Pharmaceuticals (REGN).
Shares of Amgen have gained 2% to $122.95 today after the biotech giant said that a trial showed it’s cholesterol drug works better than a placebo. Reuters has the details:
Amgen Inc’s drug from a high profile new class of experimental medicines lowered “bad” LDL cholesterol by 55 percent to 66 percent compared with a placebo in a trio of late-stage clinical trials, according to data presented on Saturday.
Amgen had previously said the drug, evolocumab, met the main goals of five late-stage trials involving some 4,000 patients by significantly outperforming placebo or another cholesterol medicine in a variety of patient populations.
Morgan Stanley’s Matthew Harrison and David Friedman note that the minimal number of “neurocognitive events” was good news for Amgen:
Lack of neurocognitives could offer some relief, but overall data as expected. We would expect a modest uptick in A[Amgen] given the very clean data. That said, we believe the key debate continues to be around the long-term market size (which depends on CV outcomes) for which we do not have an answer. We found the data in HeFH and statin intolerant patients to be the most compelling given the high baseline LDL-C (~195mg/dL). We believe this population (~500k-1M) will see the most use prior to outcomes data given the higher unmet need.
Credit Suisse analyst Jason Kantor and team call the results good news for Regeneron Pharmaceuticals version of the drug, but not necessarily its stock:
Data from [Amgen's] evolocumab program substantially derisks the anti-PCSK9 drug class, demonstrating consistent efficacy and safety across multiple Phase III trials. Provided�[Regeneron] shows similar results (highly likely), competition is likely to focus on dosing strategy, while the ultimat
- [By Ben Levisohn]
All good things must come to an end. And so it is with the S&P 500′s six-day winning streak, as AT&T (T), Intuitive Surgical (ISRG), International Game Technology (IGT), Amgen (AMGN) and Netflix (NFLX) helped lead the market lower.
Top 10 Promising Stocks To Own For 2014: Virgin Australia Holdings Ltd (VBHLF)
Virgin Australia Holdings Limited (VAH) is an Australia-based company engaged in the development and operation of domestic and international airlines. VAH�� fleet includes ATR-72, Embraer 190, Boeing 737-700, Boeing 737-800, AIRBUS A330 and Boeing 777-300ER. It product includes Airbus A330 Business Class. During the fiscal year ended June 30, 2012, the Company carried 19,468,929 guests on 216 city pairs to 52 destinations, and operated 162,817 flights. On February 22, 2012, under the proposal, all of the shares in the international airline business of Virgin Australia were transferred to a new holding company, Virgin Australia International Holdings Pty Ltd. In April 2013, it acquired 100% of the issued share capital in Skywest Airlines Ltd. In July 2013, Virgin Australia Holdings Limited announced that it has acquired 60% interest of Tiger Airways Australia Pty Limited from Tiger Airways Holdings Limited. Advisors' Opinion:- [By MARKETWATCH]
LOS ANGELES (MarketWatch) -- Australian stocks gave ground in early Friday trading, with banks broadly lower after overnight losses in the U.S., where investors worried that better-than-expected data would prompt the Federal Reserve to roll back stimulus soon. The S&P/ASX 200 (AU:XJO) lost 0.4% to 5,178.30, as National Australia Bank Ltd. (AU:NAB) (NAUBF) fell 1.8%, Australia & New Zealand Banking Group (AU:ANZ) (ANEWF) lost 0.8%, and Macquarie Group Ltd. (AU:MQG) (MCQEF) retreated 1.3%. Among the resource shares, losses for gold both in New York and in early Asian electronic trade helped send Evolution Mining Ltd. (AU:EVN) (CAHPF) down 1.9% and Kingsgate Consolidated Ltd. (AU:KCN) (KSKGF) off 4.5%, though Newcrest Mining Ltd. (AU:NCM) (NCMGF) held the drop to 0.4%. Oil prices managed a modest gain, however, resulting in a 0.2% rise for Oil Search Ltd. (AU:OSH) (OISHF) and Karoon Gas Australia Ltd. (AU:KAR) (KRNGF) , while Woodside Petroleum Ltd. (AU:WPL)
No comments:
Post a Comment